Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1291 to 1300 of 2733 total matches.
Ferric Citrate (Auryxia) for Hyperphosphatemia
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
Exams
Published by The Medical Letter, Inc. • A Nonprofit Organization
Table 1. Some Oral Drugs ...
The FDA has approved ferric citrate (Auryxia –
Keryx), an oral phosphate binder, for treatment of
hyperphosphatemia in patients with chronic kidney
disease (CKD) on dialysis. It is the second iron-based
phosphate binder to be approved in the US, and the
first that causes significant systemic absorption of
iron. Auryxia is not FDA-approved for treatment of
iron deficiency anemia.
Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016 (Issue 1485)
to conventional
therapy, but its use has been limited by serious GI
adverse effects such as ischemic colitis.1 ...
The FDA has approved eluxadoline (Viberzi – Actavis),
a mu-opioid receptor agonist and delta-opioid
receptor antagonist, for oral treatment of adults with
irritable bowel syndrome with diarrhea (IBS-D).
In Brief: Pitavastatin Magnesium (Zypitamag) for Hyperlipidemia
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018 (Issue 1549)
significantly more than less intensive
regimens. In one meta-analysis, each additional 1 mmol/L
(39 mg/dL ...
The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium (Zypitamag – Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin magnesium bioequivalent to pitavastatin calcium (Livalo), which was approved in 2009.1Statins remain the treatment of choice for most patients who require lipid-lowering therapy. Taken as an adjunct to diet modification, increased exercise, and smoking cessation, statins can reduce the risk of primary and secondary cardiovascular events and death in patients with or at high risk for...
Osmolex ER - Another Extended-Release Amantadine for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Sep 10, 2018 (Issue 1555)
of levodopa-induced
dyskinesia in patients with PD.1
Pronunciation Key
Osmolex: oz' mole ex
STANDARD ...
The FDA has approved an extended-release tablet
formulation of amantadine (Osmolex ER – Vertical/Osmotica) for once-daily treatment of Parkinson's
disease (PD) and drug-induced extrapyramidal
symptoms (EPS) in adults. An extended-release
capsule formulation of amantadine (Gocovri) was
approved in 2017 for treatment of levodopa-induced
dyskinesia in patients with PD.
Sulfonamide Cross-Reactivity
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
of
sulfanilamide. Both antibacterial and nonantibacterial
sulfonamide drugs (see Table 1) contain a sulfonamide ...
A reader has questioned why the label for the COX-2
selective NSAID celecoxib (Celebrex, and generics),
which contains a sulfonamide moiety, states that it
is contraindicated for use in patients with an allergy
to sulfonamides, while the labels of some other
sulfonamide drugs recommend either caution or no
precautions at all. The concept of cross-reactivity
among sulfonamide drugs, particularly between
antibacterial and nonantibacterial sulfonamides, has
been controversial for many years.
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
-only oral
contraceptives available in the US contain
norethindrone (Camila, and others).1 Progestin ...
The FDA has approved a progestin-only oral
contraceptive ("minipill") containing drospirenone
(Slynd – Exeltis). All other progestin-only oral
contraceptives available in the US contain
norethindrone (Camila, and others). Progestin-only oral
contraceptives are similar in efficacy to combination
oral contraceptives. They are used predominantly by
breastfeeding women and by those in whom estrogen
is poorly tolerated or contraindicated. Combination
oral contraceptives containing drospirenone and
ethinyl estradiol have been available for years.
In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
failure with reduced
ejection fraction (HFrEF).1 The indication has now
been expanded to include ...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga – AstraZeneca) was
approved by the FDA in 2020 to reduce the risk of
cardiovascular death and hospitalization for heart
failure (HF) in adults with heart failure with reduced
ejection fraction (HFrEF). The indication has now
been expanded to include a reduction in the risk
of urgent HF visits and use in adults with any left
ventricular ejection fraction (LVEF).
Med Lett Drugs Ther. 2023 Jun 26;65(1679):101-2 doi:10.58347/tml.2023.1679c | Show Introduction Hide Introduction
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
for
cardiovascular disease.1
MECHANISM OF ACTION — Inflammation is thought
to play an important role ...
Colchicine (Colcrys, and others), which has been
available in the US for decades for prophylaxis
and treatment of gout flares and other indications
in oral formulations that contain 0.6 mg of the
drug, has now been approved in 0.5-mg tablets as
Lodoco (Agepha) to reduce the risk of myocardial
infarction (MI), stroke, coronary revascularization,
and cardiovascular death in adults with established
atherosclerotic disease or multiple risk factors for
cardiovascular disease.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):156-7 doi:10.58347/tml.2023.1686b | Show Introduction Hide Introduction
Pioglitazone (Actos)
The Medical Letter on Drugs and Therapeutics • Nov 19, 1999 (Issue 1066)
dosage Cost
1
Troglitazone − Rezulin (Parke-Davis) 200 to 600 mg once
2
89.28
Rosiglitazone ...
Pioglitazone is the third thiazolidinedione ("glitazone") to be marketed in the USA for treatment of type 2 diabetes. Thiazolidinediones decrease resistance to insulin.
In Brief: Cardiovascular Safety of Varenicline (Chantix)
The Medical Letter on Drugs and Therapeutics • Aug 22, 2011 (Issue 1371)
and suicidal ideation, appears
to be the most effective drug available for treatment of
tobacco dependence.1 ...
Varenicline (Chantix), which has been associated with neuropsychiatric symptoms such as agitation, depressed mood, changes in behavior and suicidal ideation, appears to be the most effective drug available for treatment of tobacco dependence.1 Recently, the FDA warned that varenicline may also increase the risk of cardiovascular adverse events in patients with cardiovascular disease.2 This warning was based on the results of a 12-week randomized trial in 714 smokers with stable cardiovascular disease. The drug was effective in helping patients stop smoking; long-term quit rates (at 52 weeks)...
